Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Sadoff
  NCT04436276		 RCTJanssen AD26 vaccine (JNJ-78436735)placeboCOVID-19 prophylaxis (excluding children)NA
-/- inconclusive
    Interim Results of a Phase 1–2a Trial : cohort 1 (healthy adults 18-55y) and 3 (>65y). Data that are reported here were collected after the administration of the second dose (either vaccine or placebo) in cohort 1a and after the first dose in cohort 3
    ENSEMBLE (COV3001) unpublished
          NCT04505722    		 RCTJanssen AD26 vaccine (JNJ-78436735)placeboCOVID-19 prophylaxis (excluding children)some concern
    		21895/21888 conclusif
    • suggested 81 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
    • demonstrated 67 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 82 % decrease in hospitalization with a moderate degree of certainty due to some concern in risk of bias
    2 studies excluded by filtering options (0 RCT / 2 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons